Skip to main content

Matthew R. Weir, MD

Academic Title:

Professor

Primary Appointment:

Medicine

Administrative Title:

Division Head, Nephrology

Location:

UMMS N3W143

Phone (Primary):

410-328-5720

Phone (Secondary):

410-328-8717

Fax:

410-328-5685 (Fax)

Education and Training

Education

1974: B.A. University of Virginia, Charlottesville, Virginia
1978 M.D. University of Virginia , Charlottesville, Virginia

Internship

1978-1979 The Waterbury Hospital and Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT

Residency

1979-1980 Junior Assistant Resident in Medicine, The Waterbury Hospital and Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT
1980-1981 Senior Assistant Resident in Medicine, The Waterbury Hospital and Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT

Research Fellowships:

1981-1982 Clinical Nephrology Fellow, Harvard Medical School and The Brigham and Women's Hospital, Boston, MA
1982-1983 Laboratory of Immunogenetics and Transplantation, Renal Division, Harvard Medical School and The Brigham and Women's Hospital, Boston, MA

Biosketch

Matthew R. Weir, M.D. is attending physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital, Baltimore.  He is also Professor of Medicine at the University of Maryland School of Medicine.

Dr. Weir’s primary research interests include the use of antihypertensive therapy for the treatment of diabetic nephropathy, hypertensive renal injury in African Americans, cardiovascular disease in patients with chronic kidney disease, and mineralocorticoid receptor antagonism to treat atherosclerosis. He has written more than 350 manuscripts and book chapters about these topics.  He has edited 8 books on topics in nephrology, transplantation, and hypertension. He has presented at numerous international scientific association meetings, hospitals, and medical schools.

Dr. Weir currently reviews manuscripts for more than 30 major medical journals, including the American Society of Nephrology, and Archives of Internal Medicine.  He is on the editorial board of 18 journals and is Section Editor of Current Hypertension Reports and Current Opinion in Hypertension and Nephrology, and Associate Editor of Clinical Nephrology and the American Journal of Nephrology.  He has 2 active NIH supported grants from NIDDK, and one from NHLBI.  In addition, he is a member of numerous associations, including the American Society of Nephrology, the National Kidney Foundation, the American Heart Association, and the American Society of Transplantation.

Dr. Weir received his medical degree from the University of Virginia, Charlottesville.  He completed his internship and residency programs in medicine at the Waterbury and Yale-NewHavenHospitals in Connecticut, and completed his nephrology training at the Brigham and Women’s Hospital, HarvardMedicalSchool, in Boston, Massachusetts.  He then moved to then to the University of Maryland where he has been a full time faculty member since 1983.

Research/Clinical Keywords

1. Hypertension, diabetic kidney disease: developing new treatments for slowing progression of diabetic kidney disease. 2. Hypertension, African Americans: strategies to improve blood pressure control and prevent hypertensive kidney injury in African-Americans. 3. Cardiovascular disease, chronic kidney disease: understanding more about the cardiovascular risk factors and their treatment in patients with chronic kidney disease 4. Cardiovascular disease, kidney transplantation: developing strategies to prevent cardiovascular disease in recipients of kidney transplants. 5. Aldosterone atherosclerosis, mineralocorticoid receptor antagonism: studying the effects of blocking aldosterone on the progression of atherosclerosis and cardiovascular/renal disease progression.

Highlighted Publications

Narayan P, Duan B, Jiang K, Li J, Paka L, Yamin MA, Friedman SL, Weir MR, Goldberg ID. Late intervention with the small molecule BB3 mitigates postischemic kidney injury. Am J Physiol Renal Physiol. 2016 Aug 1;311(2):F352-61.

Palmer BF, Clegg DJ, Taylor SI, Weir MR. Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. J Diabetes Complications. 2016 Aug;30(6):1162-6.

Lentine KL, Villines TC, Axelrod D, Kaviratne S, Weir MR, Costa SP. Evaluation and Management of Pulmonary Hypertension in Kidney Transplant Candidates and Recipients: Concepts and Controversies. Transplantation. 2016 Mar 16. [Epub ahead of print]

Weir MR, Pearson TC, Patel A, Peddi VR, Kalil R, Scandling J, Chan L, Baliga P, Melton L, Mulgaonkar S, Waid T, Schaefer H, Youssef N, Anandagoda L, McCollum D, Lawson S, Gordon R. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. Transplantation. 2016 Mar 4.

Dias C, Moore KT, Murphy J, Ariyawansa J, Smith W, Mills RM, Weir MR. Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error. Am J Nephrol. 2016;44(2):169. Epub 2016 Aug 23.

Additional Publication Citations

Ravichandran B, Weir MR. The Tyranny of Generic Immunosuppressants. Am J Nephrol. 2016;44(3):204-5. Epub 2016 Aug 31.

Weir MR. Biomarkers for Predicting Improved Outcomes With Renal Artery Stenting. Hypertension. 2016 Sep 19. [Epub ahead of print].

Bushinsky DA, Spiegel DM, Gross C, Benton WW, Fogli J, Hill Gallant KM, Du Mond C, Block GA, Weir MR, Pitt B. Effect of Patiromer on Urinary Ion Excretion in Healthy Adults. Clin J Am Soc Nephrol. 2016 Sep 27.

Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 Sep;90(3):696-704.

Liu X, Foster MC, Tighiouart H, Anderson AH, Beck GJ, Contreras G, Coresh J, Eckfeldt JH, Feldman HI, Greene T, Hamm LL, He J, Horwitz E, Lewis J, Ricardo AC, Shou H, Townsend RR, Weir MR, Inker LA, Levey AS; CRIC (Chronic Renal Insufficiency Cohort) Study Investigators. Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD. Am J Kidney Dis. 2016 Sep 20. pii: S0272-6386(16)30374-2.

Kasiske BL, Kumar R, Kimmel PL, Pesavento TE, Kalil RS, Kraus ES, Rabb H, Posselt AM, Anderson-Haag TL, Steffes MW, Israni AK, Snyder JJ, Singh RJ, Weir MR. Abnormalities in biomarkers of mineral and bone metabolism in kidney donors. Kidney Int. 2016 Oct;90(4):861-8.

Clinical Specialty Details

  1. Complicated, resistant and refractory hypertension
  2. Cardiovascular disease in patients with chronic kidney disease or kidney transplants
  3. Home hemodialysis
  4. Chronic kidney disease

Grants and Contracts

Industry

1984

  • 1984: Marion Laboratories, $90,000. "Comparison study of Diltiazem vs Atenolol in the treatment of mild to moderate hypertension." Co-Investigator.
  • 1984: Miles Laboratories, $8,000. "Pharmacokinetic study of the renal excretion of Ciprofloxacin in patients with impaired renal function." Co-Investigator.

1985

  • 1985: Upjohn Co., $32,400. "The effects of topical Minoxidil in untreated hypertensives." Co-Investigator.
  • 1985: Ayerst Laboratories. $55,728. "Hydrochlorothiazide dose finding study with Inderal LA." Co-Investigator.
  • 1985: Syntex Laboratories. $60,000. "Nicardipine vs Propranolol in Mild to Moderate Hypertension." Co-Investigator.

1986

  • 1986: American Cyanamid, Lederle Laboratories. $63,365.76. "Safety and Dose-Finding study of Nilvadipine in Hypertension." Principal Investigator.
  • 1986: Merck, Sharp & Dohme. $18,000. "Vasotec-therapy in Mild to Moderate Hypertension." Co-Investigator.
  • 1986: Miles Laboratories, $6,000. "Pharmacokinetic Study of the renal excretion of intravenous ciprofloxacin in patients with impaired renal function." Co-Investigator.
  • 1986: Syntex Laboratories, $48,211.20. "Nicardipine vs Captopril for Hypertension in the Elderly." Co-Investigator.
  • 1986: Marion Laboratories, $77,544. "A comparative Study of Urapidil vs Placebo in Mild to Moderate Hypertension." Principal Investigator.
  • 1986: Merck, Sharp & Dohme. $63,936. "Comparison of the antihypertensive efficacy and tolerability of Vasotec and Hydrochlorothiazide and their Effects on Serum Lipids in Patients with Mild Uncomplicated Essential Hypertension." Principal Investigator.
  • 1986: CIBA-GEIGY, $72,000. "CGS 13080: Thromboxane Synthetase Inhibition Effect on Renal Function and Blood Pressure." Principal Investigator.

1987

  • 1987: E.R. Squibb & Sons, Co., $33,000. "Capozide vs Tenoretic in Mild to Moderate Hypertension." Principal Investigator.
  • 1987: Pfizer Pharmaceuticals, $58,980. "Oral Nifedipine vs IV Labetalol in Hypertensive Urgencies." Co-investigator.
  • 1987: Abbott Laboratories, $39,366. "Terazosin vs Propranolol in Elderly Hypertensives. " Co-principal Investigator.
  • 1987: Searle Laboratories, $48,000. "Calan vs Tenormin vs Capoten in Black Hypertensives." Co-principal Investigator.
  • 1987: Dupont Critical Care, $70,000. "IV Nicardipine in hypertensive urgencies." Co-investigator.
  • 1987: American Cyanamid Company, $72,072.00. "Efficacy of Nilvadipine in Hypertension." Principal Investigator.
  • 1987: Merck, Sharpe & Dohme, $100,200. "Vasotec vs. Verapamil SR in Hypertension." Principal Investigator.
  • 1987: A.H. Robins, $133,200. "Bopindolol in black hypertensives." Co-Principal Investigator.
  • 1987: Marion Laboratories, $38,400. "Diltiazem SR vs HCTZ in Hypertension." Principal Investigator.
  • 1987: Searle Laboratories $24,000. Unrestricted Educational Grant.

1988

  • 1988: Searle Laboratories $40,000. Unrestricted Education Grant.
  • 1988: E.R. Squibb & Sons, $46,476.00. "Effect of Zofenopril in Hypertension." Principal Investigator."
  • 1988: Marion Laboratories, $72,560.00. "Effect of Antihypertensive Therapy on Quality of Life in Elderly Females." Principal Investigator.
  • 1988: Marion Laboratories, $54,000.00. "Efficacy of Diltiazem/Captopril Combination in Hypertension." Principal Investigator.
  • 1988: Syntex Laboratories, $57,552.00. "Once Daily Dose of RS-10085 in Essential Hypertension." Co-Investigator.
  • 1988: Syntex Laboratories, $66,009.00. "Comparison of Nicardipine and HCTZ in the Treatment of Hypertension in Blacks." Principal Investigator.
  • 1988: Merck, Sharpe & Dohme, $122,000. "Lisinopril vs. verapamil SR in the treatment of older hypertensives." Principal Investigator.
  • 1988: Merck, Sharpe & Dohme, $40,000. "Lisinopril vs verapamil SR in the treatment of black hypertensives.” Principal Investigator.
  • 1988: Sandoz Research Institute, $9,200. Educational Grant. Principal Investigator.
  • 1988: Marion Laboratories, $52,416. "Dose evaluation of Diltiazem SR/HCTZ in combination vs single agents and placebo in the treatment of hypertension." Principal Investigator.

1989

  • 1989: Searle Laboratories, $85,536.00. "Open label study of cytotec in the prevention of NSAID-induced renal dysfunction in the elderly." Principal Investigator.
  • 1989: Marion Laboratories, $35,550.00. "Diltiazem QD dose response hypertension trial." Principal Investigator.
  • 1989: Sandoz Research Institute, $82,917.00. "A clinical study to determine the efficacy and safety of cyclosporine and its effect on renal function in patients with rheumatoid arthritis." Co-Investigator.
  • 1989: Hoffman-LaRoche, $61,200. "Efficacy of cilazapril and/or HCTZ in hypertension." Co-Principal Investigator.
  • 1989: Merck, Sharp & Dohme, $49,900. "Evaluation of Vaseretic in mild to moderate hypertension." Principal Investigator.
  • 1989: Merck, Sharp & Dohme, $79,200. "Vasotec vs Cardizem SR for treatment of hypertension." Principal Investigator.
  • 1989: Rorer Pharmaceuticals, $61,500. "Comparative study of Lozol as add-on therapy to Calan SR." Co-Principal Investigator.
  • 1989: Knoll Pharmaceuticals, Inc., $84,600. "The safety and efficacy of Trandolapril in black hypertensives." Principal Investigator.
  • 1989: CIBA-GEIGY, 61,296.00. "The safety and tolerability of CGS 12970 in renal allograft recipients." Principal Investigator.
  • 1989: American Cyanamid, $64,920. "Randomized double-blind comparative study of bisoprolol in combination with HCTZ." Principal Investigator.
  • 1989: Burroughs Welcome Co., $190,000. Retrovir in the treatment of HIV-infected patients in renal failure." Co-Investigator.
  • 1989: Parke-Davis, $204,000. "Evaluation of once vs twice daily dosing of Quinapril on renal function in patients with congestive heart failure." Co-Principal Investigator.

1990

  • 1990: Marion Laboratories, Inc. $68,500. "Dose response characteristics to TA-3090 in hypertensives." Principal Investigator.
  • 1990: Glaxo, Inc. $104,300. "Isradipine vs HCTZ in the regression of left ventricular hypertrophy." Co-Principal Investigator.
  • 1990: Glaxo, Inc. $156,000. "Impact of salt sensitivity on the effects of isradipine on blood pressure and renal hemodynamics. Principal Investigator.
  • 1990: ICI Pharma. $31,200. "Lisinopril vs diltiazem SR in the treatment of moderate to severe hypertension." Principal Investigator.
  • 1990: Bristol Myers Squibb, Inc. $68,900. "A comparison of fosinopril and verapamil SR on blood pressure and protein excretion in hypertensive patients with Type II diabetes mellitus." Principal Investigator.
  • 1990:: Knoll Pharmaceuticals, $58,000. "Open-label study of the long-term safety of oral trandolapril therapy in patients with mild to moderate essential hypertension." Principal Investigator.
  • 1990: Roerig, $203,100. "A multicenter evaluation of the efficacy and side effect profile of doxazosin vs enalapril as initial antihypertensive therapy in patients with mild-to-moderate primary hypertension.” Principal Investigator.
  • 1990: Hoffman-LaRoche, $32,100. "Multicenter, placebo controlled study evaluating the antihypertensive effect and safety of the cilazapril/hydrochlorothiazide combination. Principal Investigator.
  • 1990: Knoll Pharmaceuticals, $60,500. "Double-blind, randomized, placebo-controlled, factorial study to evaluate the safety and efficacy of oral trandolapril combination with verapamil." Principal Investigator.
  • 1990: Merck, Sharpe & Dohme, $201,600. "Comparison of the efficacy and tolerability of lisinopril and extended-release nifedipine in mild to moderate uncomplicated essential hypertension." Principal Investigator

1991

  • 1991: Lederle Laboratories, $26,200. "Isolated systolic hypertension in the elderly: a randomized, double- blind, placebo controlled trial of once-a-day Verelan verapamil 120 mg and 240 mg capsules in the treatment of isolated systolic hypertension in patients age 60 years and older." Principal Investigator
  • 1991: ICI Pharma, $62,300. "Controlled clinical trial comparing Zestoretic 10-12.5 and Zestoretic 10-25 (lisinopril/hydrochlorothiazide) to each of the monocomponents and placebo in the treatment of mild to moderate essential hypertension." Principal Investigator.
  • 1991: Knoll Pharmaceuticals, $55,200. "Open-label study of the long-term safety of oral trandolapril in combination with verapamil." Principal Investigator.
  • 1991: Knoll Pharmaceuticals, $59,600. "Double-blind, randomized, placebo-controlled, five-way parallel dose-ranging study to evaluate the safety and efficacy of oral trandolapril therapy (4,8,12,16 mg/day) in black patients with mild to moderate essential hypertension." Principal Investigator.
  • 1991: Knoll Pharmaceuticals, $56,700. "Evaluation of the safety and efficacy of oral trandolapril in combination with verapamil (Isoptin SR) in patients with severe essential hypertension. Principal Investigator.
  • 1991: Marion Merrell Dow, $19,200. "Assessment of the safety and efficacy of diltiazem QD in patients whose hypertension is controlled by Cardizem SR. Principal Investigator.
  • 1991: CIBA-GEIGY, $50,600. "A randomized, double-blind, placebo controlled, parallel-group comparison of monotherapy and combined therapy of benazepril 5 mg once daily and amlodipine 2.5 mg once daily for the treatment of patients with essential hypertension. Co-Principal Investigator.

1992

  • 1992: Merck, Sharp & Dohme, $12,000. "Efficacy and tolerability of extended release felodipine in adult patients with mild to moderate uncomplicated hypertension." Principal Investigator.
  • 1992: CIBA Geigy, $47,712. "A randomized, double-blind, placebo controlled, parallel-group comparison of monotherapy and combined therapy of benazepril 20 mg once daily and amlodipine 5 mg once daily in black patients with essential hypertension." Co-Principal Investigator.
  • 1992: Warner Lambert Company, $167,100. "The safety and efficacy of once daily quinapril for the treatment of mild, uncomplicated hypertension. Principal Investigator."
  • 1992:: R.W. Johnson Pharmaceutical Research Institute, $57,400. "A phase II double-blind titration comparison of perindopril erbumine and enalapril maleate in patients with mild to moderate hypertension." Principal Investigator.
  • 1992: Merck, Sharpe Dohme, $12,000. "Efficacy and tolerability of simvastatin in the treatment of primary hypercholesterolemia." Principal Investigator
  • 1992: Marion Merrell Dow, $22,700. "A comparative trial of the safety and efficacy of Cardizem CD and felodipine in elderly hypertensive patients." Principal Investigator.
  • 1992: Hoechst-Roussel Pharmaceuticals, Inc. $135,000. "The impact of ramipril and nifedipine gits and high and low sodium intake on blood pressure, proteinuria, and renal hemodynamics in black hypertensives with renal dysfunction." Principal Investigator.
  • 1992: Wyeth-Ayerst Laboratories, $42,000. "A multicenter, randomized, double-blind, placebo-controlled study to determine the effect of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with mild to moderate hypertension controlled by verelan." Principal Investigator.
  • 1992: Hoffman-LaRoche, Inc, $33,912. "A comparison of RO 40-5967 versus Diltiazem CD and placebo for the treatment of essential hypertension.” Principal Investigator
  • 1992: Bristol Myers Squibb U.S. Pharmaceutical Division, $25,416. "A double- blind, randomized trial comparing once daily combination Captopril plus Hydrochlorothiazide versus Nifedipine GITS in black patients with mild-to-moderate essential hypertension." Co-Investigator.

1993

  • 1993: Sandoz Pharmaceuticals Corporation, $20,300. "Impact of Isradipine and sodium intake on blood pressure proteinuria and renal hemodynamics in hypertensive renal transplant patients." Principal Investigator
  • 1993: Parke-Davis, $16,800. Impact of Quinapril and high and low sodium intake on blood pressure, proteinuria, and renal hemodynamics in hypertensive renal transplant recipients." Principal Investigator
  • 1993: Merck & Co., Inc, $21,200. "A multicenter, prospective, double-blind, randomized, parallel, comparison study of the quality of life and the efficacy and tolerability of 40 mg of Lovastatin versus 40 mg Pravastatin in male patients with primary hypercholesterolemia (types IIa and IIb)." Principal Investigator.
  • 1993: Merck & Co., $24,000. "A multicountry, double-blind study to evaluate the quality of life of hypercholesterolemic patients treated with simvastatin or pravastatin." Principal Investigator.
  • 1993: Advanced Metabolic Systems, $193,136. "Anti-nephropathic effects of chronic intermittent intravenous insulin therapy in type I diabetics." Principal Investigator.
  • 1993: Sandoz Pharmaceuticals, $92,280. "Dietary salt and blood pressure control with isradipine or enalapril." Principal Investigator.
  • 1993: Lederle Laboratories, $58,320. "Efficacy and safety of verelan vs cardizem in hypertension." Principal Investigator.
  • 1993: Bristol-Myers Squibb, $46,368. "A multicenter 8-week study of the antihypertensive activity and safety of BMS-186295/SR 47436 in mild to moderate hypertensives. Principal Investigator.
  • 1993: Sankyo U.S.A. Corporation, $36,800. Efficacy and safety of temocapril alone and in combination with hydrochlorothiazide. Principal Investigator.
  • 1993: Hoffmann LaRoche, Inc., #76,800. "Long term safety and efficacy of Ro-40-5967 in hypertension. Principal Investigator.
  • 1993: Marion Merrell Dow Inc., $22,410. "A comparative trial of the safety and efficacy of cardizem CD and amlodipine in older patients." Principal Investigator.
  • 1993: Knoll Pharmaceuticals, $108,432. "Antihypertensive/antiproteinuric effects of verapamil and trandolapril." Principal Investigator.
  • 1993: Bristol-Myers Squibb, $75,408. "A multicenter 8-week study of the antihypertensive activity and safety of BMS-186295 in mild to moderate hypertension." Principal Investigator.

1994

  • 1994: Bristol-Myers Squibb, $45,548. "Dose-ranging study II: A multicenter trial of the antihypertensive activity and safety of 100, 200, and 300 mg SR 47436 (BMS-186295) in mild-to-moderate hypertension." Principal Investigator.
  • 1994: Marion Merrell Dow Inc., $57,960. "Diltiazem ER/Enalapril combination therapy in hypertensive patients not responding adequately to diltiazem CD (Cardizem CD) monotherapy." Principal Investigator.
  • 1994: ZENECA, $35,616. "A placebo-controlled study assessing the treatment effects of lisinopril versus hydrochlorothiazide (HCTZ) in obese patients with hypertension - Trophy 1262US/0004." Principal Investigator
  • 1994: Wyeth-Ayerst, $56,640. "A randomized, double-blind, placebo-controlled, multicenter, dose titration trial of ANA-756 in patients with essential hypertension." Principal Investigator
  • 1994: CIBA-GEIGY, $47,910. "Randomized, double-blind, placebo-controlled, parallel-group trial comparing valsartan 20 mg, 80 mg, 160 mg, and 320 mg to placebo in patients with essential hypertension followed by an open-label extension of 52 weeks duration." Principal Investigator.
  • 1994: Parke-Davis, $47,140. "A double-blind, randomized, comparative study to examine the single agent efficacy and tolerability of Accupril (quinapril), versus placebo for the treatment of mild to moderate hypertension in black and white subjects. (Protocol 906-379). Accupril in minorities (AIM) project." Co-Investigator.

1995

  • 1995: Bristol-Meyers Squibb/Medex, $55,200. "Metformin hydrochloride vs. placebo in non-insulin dependent diabetics." Co-Investigator
  • 1995: Merck, $13,980. "COZAAR and HYZAAR vs. Procardia XL in patients with hypertension." Principal Investigator.
  • 1995: Merck, 11,050. "COZAAR and HYZAAR vs. Procardia XL in elderly patients with hypertension." Principal Investigator.
  • 1995: Lederle/Medex,$40,320. "Verelan vs Norvasc in Women with Hypertension." Principal Investigator.
  • 1995: Wyeth-Ayerst, $75,650. "A randomized, double-blind, placebo-controlled, multicenter, dose titration trial of ANA-756 in patients with essential hypertension." Principal Investigator.
  • 1995: Bristol-Myers Squibb, $14,730. Antihypertensive activity and Safety of Irbesartan in patients with hypertension. Principal Investigator.
  • 1995: Medex, $16.667. Multicenter Trial of HCTZ (12.5mg). Principal Investigator.
  • 1995: Bristol-Myers Squibb, $83,333. Phase II study of the treatment of Acute Renal Graft Rejection. Principal Investigator.
  • 1995: Wyeth Ayerst, Direct $114,812/Indirect $28,628. ANA‑756 (304) vs Atenolol in Hypertensives. Principal Investigator
  • 1995: Merck & Co, Direct $15,401/Indirect $3,715. Simvastatin and Fluvastatin(Zocor). Principal Investigator.
  • 1995: Merck & Co, Direct $6,200/Indirect $1,550. Losartan effectiveness and tolerability (LET). Principal Investigator.
  • 1995: Bristol-Myers Squibb, Direct $28,280/Indirect $7,070. Irbesartan in Hypertensives-050. Principal Investigator.

1996

  • 1996: Bristol-Myers Squibb, Direct $28,750/Indirect $5,750.Dual Metalloprotease Inhibitor, BMS‑186716. Principal Investigator.
  • 1996: Forest Laboratories, Inc. Direct $27,083/Indirect $5,167. Calcium Channel Blockers in reducing Proteinuria. Principal Investigator.
  • 1996: Merck & Co, Direct $33,178/ Indirect $8,294. Losartan Intervention for Endpoint Reduction (LIFE). Principal Investigator.
  • 1996: Bristol-Myers Squibb, Direct $57,760/ Indirect $14,440. Irbesartan in Type II Diabetics with Nephropathy. Principal Investigator.
  • 1996: Merck & Co, Direct $71,250/Indirect $14,250. Losartan in patients with Diabetes Mellitus. Principal Investigator.
  • 1996: Bristol-Myers Squibb, Direct $43,639/ Indirect $10,909. Irbesartan in Mild to Moderate Hypertensives. Principal Investigator.
  • 1996: Astra Merck, Direct $55,373 Indirect $13,843. Fixed Combination of Candesartan and HCTZ. Principal Investigator.
  • 1996: Bristol-Myers Squibb, Direct $29,167 Indirect $5,833. Multicenter, randomized, forced titration trial antihypertensive efficacy and safety Irbesartan compared with losartan for treatment of mild to moderate hypertensives-088. Principal Investigator.
  • 1996: Merck & Co, Direct $45,625 Indirect $9,125. Study of the effects of the non-steroidal anti-inflammatory drug indomethacin on the anti-hypertensive response to losartan versus captopril in essential hypertension. Principal Investigator.
  • 1996: Searle, Direct $24,000 Indirect $6,000. Revised clinical protocol for controlled onset verapamil investigation of cardiovascular endpoints. Principal Investigator.
  • 1996: Merck & Co, Direct $51,067 Indirect $10,213. African-American ECHO substudy for LIIFE. Principal Investigator.

1997

  • 1997: Roche, Direct $181,940 Indirect $36,388. Cooperative Clinical Trials in Adult Transplantation (CCTAT) Hoffman LaRoche steroid sparing trial. Principal Investigator.
  • 1997: Roche, Direct $150,000 Indirect $30,000. MMF rescue therapy in chronic rejection. Principal Investigator.
  • 1997: Merck & Co, Direct $29,167 Indirect $5,833. The influence of losartan and enalapril on blood pressure and proteinuria in hypertensives with normal renal function. Principal Investigator.
  • 1997: Merck & Co, Direct $29,167 Indirect $5,833. The influence of dietary salt and losartan therapy on blood pressure and proteinuria in hypertensives with normal renal function. Principal Investigator.
  • 1997: Novartis, Direct $14,350 Indirect $2,870. A randomized, double blind, placebo-controlled, forced-titration parallel safety efficacy of Lotrel 5/20 mg to Lotrel 10/20 mg once daily in patients with hypertension. Co-principal Investigator.
  • 1997: ISHIB/Bayer, Direct $33,340 Indirect $6,660. Calcium antagonists in Blacks. Co-principal Investigator.
  • 1997: Hoffman-La Roche, Direct $86,792 Indirect $17,358. Immunosuppression Withdrawal in Stable Renal Allograft Recipients Treated with Triple Therapy. Principal Investigator.
  • 1997: Covance, Direct $45,500 Indirect $9,100. Placebo Controlled Study of Moxonidine in Stage 1 and Stage 2 Hypertension. Co-principal Investigator.
  • 1997: Novartis, Direct $117,000 Indirect $23,400. Comparative Effects of Diuretics and Ace Inhibitors to Alleviate Ankle Edema Due to Calcium Antagonist. Principal Investigator.
  • 1997: Novartis, Direct $106,425 Indirect $21,285. The influence of dietary salt and valsartan therapy on blood pressure and proteinuria in hypertensive African Americans. Principal Investigator.

1998

  • 1998: Astra Merck, Direct $55,090 Indirect $11,018. The ABC Study of Hypertension: Protocol 140." Co-principal Investigator.
  • 1998: Smith Kline Beecham, Direct $31,967 Indirect $6,393. A Double Blind Efficacy and Safety Study of Baycol (cerivastatin) & Pravacol (pravastatin) in treatment of hypercholesterolemia. Co-principal Investigator.
  • 1998: Merck & Co., Direct $31,302 Indirect $6,260. Losartan in African American Patients with Mild-to-Moderate Hypertension. Co-principal Investigator.
  • 1998: Novartis, Direct $65,494 Indirect $13,099. VALUE (Diovan Antihypertensive Long-term Use Evaluation). Co-principal Investigator.
  • 1998: Covance, Direct $36,000 Indirect $7,200. Open Label Study of Neoral as Primary Immunosuppressant Therapy in Transplant Patients Who are Unable to Maintain Immunosuppression. Co-principal Investigator.
  • 1998: Merck & Co., Direct $11667 Indirect $2,333. A Triple-Blind, Randomized, Parallel, Efficacy Study of Losartan Versus Irbesartan in Patients With Mild to Moderate Essential Hyperten. Coz442. Principal Investigator.
  • 1998: Smith Kline Beecham, Direct $71,250 Indirect $14,250. Forced Titration Study of Teveten (Eprosartan mesylate; SK&F 108566-J) at Doses of 600 mg and 1200 mg Once Daily in African Americans. Principal Investigator.
  • 1998: Bristol-Myers Squibb, Direct $29,167 Indirect $5,833. A Study of the antiproteinuric Effects of Omapatrilat and Amlodipine in Type II Diabetic with Hypertension and Microalbuminuria. Principal Investigator.

1999

  • 1999: Merck-Sharpe and Dohme, Direct $26,220. Losartan and enalapril alone in combination on blood pressure and proteinuria in hypertensive-normal renal function. Principal Investigator.
  • 1999: Fujisawa Healthcare, Direct $100,000. Prograf as secondary intervention in chronic allograft nephropathy. Prinicipal Investigator.
  • 1999: Hoechst Marion Roussel, Direct$23,760. Dose response with intravenous HMR396 in Anemic Patients. Principal Investigator.
  • 1999: Astra Pharmaceuticals Products, $94,500. A comparison of angiotensin receptor blockade vs calcium channel blockade on allograft nephropathy. Principal Investigator.
  • 1999: Novartis. Tolerability of ERL080A.

2000

  • 2000: Fujisawa, 100,000 Direct, 20,000 Indirect. Prograf vs cyclosporine in patients with renal failure. Principal Investigator
  • 2000: Hoffmann-LaRoche Company, 129,167 Direct, 25,8333 Indirect. Treatment for chronic allograft nephropathy. Principal Investigator
  • 2000: Hoffmann-LaRoche Company, 86,500 Direct, 17,300 Indirect. Immunosuppression in renal allograft triple therapy. Principal Investigator
  • 2000: Merck, Sharp and Dohme, 10.662 Direct, 2,133 Indirect. Losartan intervention for endpoint reduction in hypertension. Principal Investigator
  • 2000: Merck, Sharp and Dohme, 9,510 Direct, 1,902 Indirect. Losartan in patients with non-insulin dependent diabetes.

2001

  • 2001: Biovail Laboratories. Diltiazem HCL Extended Release Capsules.
  • 2001: Novartis. Enalapril in Treatment of Hypertension in Type 2 Diabetics.
  • 2001: Novartis Pharmaceuticals, University of Maryland School of Medicine, The National Living Renal Transplant Registry, Co-Medical Director. 7/1/2001: – 6/30/2003:. The major goal of this project is to conduct a multi-center Web-based registry to track the longitudinal outcome of living renal transplant recipients who are treated with or without basiliximab (Simulect).

Other Time Frames:

  • 1996-2000: Bristol-Myers Squibb, IDNT Study
  • 1996-2000: Merck Sharp & Dohme, RENAAL Study
  • 1996-2001: Novartis Pharmaceuticals VALUE Study
  • 1996-2000: Merck Sharp & Dohme, LIFE Study
  • 2006-2009: Roche Pharmaceuticals, STN Trial